Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339165 | 1.00 | KMT2A (0.36) | KMT2AALOX15BLMPMP22PAOX | |
| SCHEMBL21312920 | 0.78 | ALOX15 (0.46) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL5791770 | 0.78 | ALOX15 (0.52) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL28494490 | 0.76 | KMT2A (0.43) | KMT2AALOX15BLMPMP22CYP2C19 | |
| SCHEMBL7907461 | 0.74 | DPP7 (0.42) | DPP7 | |
| SCHEMBL10891103 | 0.72 | KMT2A (0.48) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL6742412 | 0.72 | KMT2A (0.48) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL25950295 | 0.71 | CYP2C19 (0.52) | KMT2APAOXCYP2C19CYP1A2MEN1 | |
| SCHEMBL23929280 | 0.69 | CYP2C19 (0.50) | KMT2APAOXCYP2C19CYP1A2MEN1 | |
| SCHEMBL16306515 | 0.69 | CYP2C19 (0.50) | KMT2APAOXCYP2C19CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | KMT2A 1577/4885ALOX15 1673/4885BLM 1571/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | KMT2A 3667/4885ALOX15 1623/4885BLM 2975/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | KMT2A 3667/4885ALOX15 1623/4885BLM 2975/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | KMT2A 3667/4885ALOX15 1623/4885BLM 2975/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | KMT2A 3667/4885ALOX15 1623/4885BLM 2975/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | KMT2A 3249/4885ALOX15 1065/4885BLM 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.